Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetesRUTHERFORD, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE ...

Glucotrack, Inc. has announced the successful completion of its first human clinical study for a continuous blood glucose monitor (CBGM), which is uniquely placed in the subclavian vein for real ...

Glucotrack (GCTK) announced the successful completion of its first in human clinical study, marking a significant milestone in continuous ...

Goode, PhD, President & Chief Executive Officer of Glucotrack. “With these positive results, the promise of continuous blood glucose monitoring is one step closer to reality.” The prospective ...

Goode, PhD, President & Chief Executive Officer of Glucotrack. “With these positive results, the promise of continuous blood glucose monitoring is one step closer to reality.” The prospective single ...